Peripheral proteomic changes after electroconvulsive seizures in a rodent model of non-response to chronic fluoxetine
Major depressive disorder (MDD) is the psychiatric disorder with the highest prevalence in the world. Pharmacological antidepressant treatment (AD), such as selective serotonin reuptake inhibitors [SSRI, i.e., fluoxetine (Flx)] is the first line of treatment for MDD. Despite its efficacy, lack of AD...
Main Authors: | Rodolphe H. Lebeau, Indira Mendez-David, Laura Kucynski-Noyau, Céline Henry, David Attali, Marion Plaze, Romain Colle, Emmanuelle Corruble, Alain M. Gardier, Raphaël Gaillard, Jean-Philippe Guilloux, Denis J. David |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.993449/full |
Similar Items
-
Patients’, Carers’, and the Public’s Perspectives on Electroconvulsive Therapy
by: Chris Griffiths, et al.
Published: (2019-05-01) -
Impact of Adjunctive VNS on Drug Load, Depression Severity, and Number of Neuromodulatory Maintenance Treatments
by: Erhan Kavakbasi, et al.
Published: (2024-02-01) -
A model for the management of difficult to treat depression
by: H. Mcallister-Williams
Published: (2021-04-01) -
Intravenous Ketamine Therapy vs. Electroconvulsive Therapy in Depressive Cases
by: Gholam Reza Kheirabadi, et al.
Published: (2012-01-01) -
ELECTROCONVULSIVE THERAPY IN ELDERLY PERSONS WITH DEPRESSION: AN EXPERIENCE
by: Zeyne Alves Pires Scherer, et al.
Published: (2011-06-01)